Cell Line Development Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

Description

Persistence Market Research has recently released an extensive analysis of the global Cell Line Development Market, presenting a detailed overview of critical market dynamics, growth catalysts, hurdles, and emerging patterns. This report furnishes invaluable insights into the framework of the cell line development market, showcasing exclusive data and metrics projecting the market's trajectory from 2023 to 2030.

The global Cell Line Development market is forecast to expand at a CAGR of 6.0% and thereby increase from a value of US$3.68 billion in 2023 to US$5.53 billion by the end of 2030.

Key Insights:

Cell Line Development Market Size (2023 Estimate): USD 3.68 Billion
Predicted Market Value (2030 Forecast): US$ 5.53 Billion
Global Market Growth Rate (CAGR 2023 to 2030): 6.0%
Historical Market Growth Rate (CAGR 2018 to 2022): 3.5%

Cell Line Development Market - Report Scope:

The cell line development market encompasses a diverse array of techniques and methodologies aimed at producing stable and reproducible cell lines for various applications in biopharmaceuticals, academic research, and biotechnology. These cell lines serve as foundational tools for drug discovery, biologics production, and disease modeling. Market expansion is propelled by escalating demand for biopharmaceuticals, continuous advancements in cell line engineering technologies, and the emergence of precision medicine. The cell line development market remains dynamic and innovative, adapting to evolving industry demands and scientific breakthroughs.

Market Growth Drivers:

The global cell line development market is primarily propelled by the burgeoning demand for biologics and biosimilars. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and viral vectors, constitute a significant portion of the pharmaceutical pipeline. As the healthcare sector increasingly relies on biologics for treating various diseases, there is a corresponding surge in the need for robust and scalable cell lines to facilitate bioproduction. Moreover, technological advancements such as genome editing and automation are streamlining cell line development processes, fostering market growth.

Market Restraints:

Despite substantial growth prospects, the cell line development market encounters challenges related to regulatory compliance and ethical considerations. Regulatory agencies impose stringent guidelines governing the use of cell lines in biopharmaceutical production to ensure product safety and efficacy. Compliance with these regulations necessitates extensive testing and validation, elongating the drug development timeline and elevating operational costs for market participants. Ethical concerns surrounding the use of certain cell lines, particularly those derived from embryonic sources, further complicate the landscape, prompting researchers to explore alternative methods and ethical cell line sources.

Market Opportunities:

The global cell line development market stands poised to capitalize on emerging opportunities in personalized medicine and regenerative therapies. With the advent of precision medicine, there is a growing emphasis on tailoring treatments to individual patients based on their genetic makeup and disease characteristics. This paradigm shift underscores the importance of patient-derived cell lines and organoids for drug screening and therapy optimization. Additionally, regenerative medicine holds promise for leveraging cell lines to develop tissue-engineered constructs and cell-based therapies for tissue repair and organ transplantation, presenting novel avenues for market expansion.

Key Questions Addressed in the Report:

Which regions are projected to lead the cell line development market in the foreseeable future?
What factors are driving the demand for cell lines in biopharmaceutical research and production?
How will emerging trends impact the global cell line development market?
Who are the prominent players shaping the landscape of the cell line development market?
What strategies are major market players employing to fortify their positions in the cell line development sector?

Competitive Landscape and Business Strategies:

Major players in the global cell line development market, including Thermo Fisher Scientific Inc., Lonza Group Ltd., and Merck KGaA, prioritize innovation and strategic partnerships to gain a competitive edge. These companies invest substantially in research and development to enhance cell line engineering platforms, streamline production workflows, and address evolving customer needs. Furthermore, strategic collaborations with biopharmaceutical companies and research institutions enable market players to expand their product portfolios, access new markets, and leverage complementary expertise to accelerate innovation and market penetration.

Key Companies Profiled:

STEMCELL Technologies
BioIVT LLC
Novus Biologicals
Rockland Immunochemicals
GenScript
BiologicsCorp
Horizon Discovery
Synthego
AcceGen
Promega
FenicsBIO
InvivoGen

Cell Line Development Market Segmentation:

By Product:

Immunotherapy Cell Lines
GPCR Cell Lines
Cell Signaling Pathway Cell Lines
Gene Knockout Cell Lines
Ion Channel Cell Lines
Cancer Cell Lines
Others

By Application:

Drug Discovery & Development
Basic Research
Toxicity Screening
Biopharmaceutical Production
Tissue Engineering
Forensic Testing

By End-User:

Biopharmaceutical Companies
Contract Research Organization
Academic & Research Institutes
Forensic Science Laboratories
Diagnostic Laboratories

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33909

1. Executive Summary

1.1. Global Cell Line Development Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Cell Line Development Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Application Landscape

3. Global Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Cell Line Development Market Outlook: Product
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
  - 3.3.3.1. Immunotherapy Cell Lines
  - 3.3.3.2. GPCR Cell Lines
  - 3.3.3.3. Cell Signaling Pathway Cell Lines
  - 3.3.3.4. Gene Knockout Cell Lines
  - 3.3.3.5. Ion Channel Cell Lines
  - 3.3.3.6. Cancer Cell Lines
  - 3.3.3.7. Others
3.4. Market Attractiveness Analysis: Product
3.5. Global Cell Line Development Market Outlook: Application
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Application, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
  - 3.5.3.1. Drug Discovery & Development
  - 3.5.3.2. Basic Research
  - 3.5.3.3. Toxicity Screening
  - 3.5.3.4. Biopharmaceutical Production
  - 3.5.3.5. Tissue Engineering
  - 3.5.3.6. Forensic Testing
3.6. Market Attractiveness Analysis: Application
3.7. Global Cell Line Development Market Outlook: End-User
- 3.7.1. Introduction / Key Findings
- 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End-User, 2018 - 2022
- 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
  - 3.7.3.1. Biopharmaceutical Companies
  - 3.7.3.2. Contract Research Organization
  - 3.7.3.3. Academic & Research Institutes
  - 3.7.3.4. Forensic Science Laboratories
  - 3.7.3.5. Diagnostic Laboratories
3.8. Market Attractiveness Analysis: End-User

4. Global Cell Line Development Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia and Oceania
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Product
- 5.3.3. By Application
- 5.3.4. By End-User
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 5.5.1. Immunotherapy Cell Lines
- 5.5.2. GPCR Cell Lines
- 5.5.3. Cell Signaling Pathway Cell Lines
- 5.5.4. Gene Knockout Cell Lines
- 5.5.5. Ion Channel Cell Lines
- 5.5.6. Cancer Cell Lines
- 5.5.7. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 5.6.1. Drug Discovery & Development
- 5.6.2. Basic Research
- 5.6.3. Toxicity Screening
- 5.6.4. Biopharmaceutical Production
- 5.6.5. Tissue Engineering
- 5.6.6. Forensic Testing
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 5.7.1. Biopharmaceutical Companies
- 5.7.2. Contract Research Organization
- 5.7.3. Academic & Research Institutes
- 5.7.4. Forensic Science Laboratories
- 5.7.5. Diagnostic Laboratories
5.8. Market Attractiveness Analysis

6. Europe Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Product
- 6.3.3. By Application
- 6.3.4. By End-User
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkiye
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 6.5.1. Immunotherapy Cell Lines
- 6.5.2. GPCR Cell Lines
- 6.5.3. Cell Signaling Pathway Cell Lines
- 6.5.4. Gene Knockout Cell Lines
- 6.5.5. Ion Channel Cell Lines
- 6.5.6. Cancer Cell Lines
- 6.5.7. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 6.6.1. Drug Discovery & Development
- 6.6.2. Basic Research
- 6.6.3. Toxicity Screening
- 6.6.4. Biopharmaceutical Production
- 6.6.5. Tissue Engineering
- 6.6.6. Forensic Testing
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 6.7.1. Biopharmaceutical Companies
- 6.7.2. Contract Research Organization
- 6.7.3. Academic & Research Institutes
- 6.7.4. Forensic Science Laboratories
- 6.7.5. Diagnostic Laboratories
6.8. Market Attractiveness Analysis

7. East Asia Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Product
- 7.3.3. By Application
- 7.3.4. By End-User
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 7.5.1. Immunotherapy Cell Lines
- 7.5.2. GPCR Cell Lines
- 7.5.3. Cell Signaling Pathway Cell Lines
- 7.5.4. Gene Knockout Cell Lines
- 7.5.5. Ion Channel Cell Lines
- 7.5.6. Cancer Cell Lines
- 7.5.7. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 7.6.1. Drug Discovery & Development
- 7.6.2. Basic Research
- 7.6.3. Toxicity Screening
- 7.6.4. Biopharmaceutical Production
- 7.6.5. Tissue Engineering
- 7.6.6. Forensic Testing
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 7.7.1. Biopharmaceutical Companies
- 7.7.2. Contract Research Organization
- 7.7.3. Academic & Research Institutes
- 7.7.4. Forensic Science Laboratories
- 7.7.5. Diagnostic Laboratories
7.8. Market Attractiveness Analysis

8. South Asia & Oceania Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Product
- 8.3.3. By Application
- 8.3.4. By End-User
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 8.5.1. Immunotherapy Cell Lines
- 8.5.2. GPCR Cell Lines
- 8.5.3. Cell Signaling Pathway Cell Lines
- 8.5.4. Gene Knockout Cell Lines
- 8.5.5. Ion Channel Cell Lines
- 8.5.6. Cancer Cell Lines
- 8.5.7. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 8.6.1. Drug Discovery & Development
- 8.6.2. Basic Research
- 8.6.3. Toxicity Screening
- 8.6.4. Biopharmaceutical Production
- 8.6.5. Tissue Engineering
- 8.6.6. Forensic Testing
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 8.7.1. Biopharmaceutical Companies
- 8.7.2. Contract Research Organization
- 8.7.3. Academic & Research Institutes
- 8.7.4. Forensic Science Laboratories
- 8.7.5. Diagnostic Laboratories
8.8. Market Attractiveness Analysis

9. Latin America Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Product
- 9.3.3. By Application
- 9.3.4. By End-User
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 9.5.1. Immunotherapy Cell Lines
- 9.5.2. GPCR Cell Lines
- 9.5.3. Cell Signaling Pathway Cell Lines
- 9.5.4. Gene Knockout Cell Lines
- 9.5.5. Ion Channel Cell Lines
- 9.5.6. Cancer Cell Lines
- 9.5.7. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 9.6.1. Drug Discovery & Development
- 9.6.2. Basic Research
- 9.6.3. Toxicity Screening
- 9.6.4. Biopharmaceutical Production
- 9.6.5. Tissue Engineering
- 9.6.6. Forensic Testing
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 9.7.1. Biopharmaceutical Companies
- 9.7.2. Contract Research Organization
- 9.7.3. Academic & Research Institutes
- 9.7.4. Forensic Science Laboratories
- 9.7.5. Diagnostic Laboratories
9.8. Market Attractiveness Analysis

10. Middle East & Africa Cell Line Development Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Product
- 10.3.3. By Application
- 10.3.4. By End-User
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
- 10.5.1. Immunotherapy Cell Lines
- 10.5.2. GPCR Cell Lines
- 10.5.3. Cell Signaling Pathway Cell Lines
- 10.5.4. Gene Knockout Cell Lines
- 10.5.5. Ion Channel Cell Lines
- 10.5.6. Cancer Cell Lines
- 10.5.7. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Application, 2023 - 2030
- 10.6.1. Drug Discovery & Development
- 10.6.2. Basic Research
- 10.6.3. Toxicity Screening
- 10.6.4. Biopharmaceutical Production
- 10.6.5. Tissue Engineering
- 10.6.6. Forensic Testing
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By End-User, 2023 - 2030
- 10.7.1. Biopharmaceutical Companies
- 10.7.2. Contract Research Organization
- 10.7.3. Academic & Research Institutes
- 10.7.4. Forensic Science Laboratories
- 10.7.5. Diagnostic Laboratories
10.8. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition GPCR Cell Lines
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. BPS Bioscience, Inc.
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Thermo Fisher Scientific Inc.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. ATCC (American Type Culture Collection)
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. Sigma-Aldrich (Merck Group Company)
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Lonza
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. STEMCELL Technologies
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. BioIVT LLC
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. Novus Biologicals
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Rockland Immunochemicals
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. GenScript
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy
- 11.3.11. BiologicsCorp
  - 11.3.11.1. Overview
  - 11.3.11.2. Segments and Product
  - 11.3.11.3. Key Financials
  - 11.3.11.4. Market Developments
  - 11.3.11.5. Market Strategy
- 11.3.12. Horizon Discovery
  - 11.3.12.1. Overview
  - 11.3.12.2. Segments and Product
  - 11.3.12.3. Key Financials
  - 11.3.12.4. Market Developments
  - 11.3.12.5. Market Strategy
- 11.3.13. Synthego
  - 11.3.13.1. Overview
  - 11.3.13.2. Segments and Product
  - 11.3.13.3. Key Financials
  - 11.3.13.4. Market Developments
  - 11.3.13.5. Market Strategy
- 11.3.14. AcceGen
  - 11.3.14.1. Overview
  - 11.3.14.2. Segments and Product
  - 11.3.14.3. Key Financials
  - 11.3.14.4. Market Developments
  - 11.3.14.5. Market Strategy
- 11.3.15. Promega
  - 11.3.15.1. Overview
  - 11.3.15.2. Segments and Product
  - 11.3.15.3. Key Financials
  - 11.3.15.4. Market Developments
  - 11.3.15.5. Market Strategy
- 11.3.16. FenicsBIO
  - 11.3.16.1. Overview
  - 11.3.16.2. Segments and Product
  - 11.3.16.3. Key Financials
  - 11.3.16.4. Market Developments
  - 11.3.16.5. Market Strategy
- 11.3.17. InvivoGen
  - 11.3.17.1. Overview
  - 11.3.17.2. Segments and Product
  - 11.3.17.3. Key Financials
  - 11.3.17.4. Market Developments
  - 11.3.17.5. Market Strategy
- 11.3.18. Abcam plc.
  - 11.3.18.1. Overview
  - 11.3.18.2. Segments and Product
  - 11.3.18.3. Key Financials
  - 11.3.18.4. Market Developments
  - 11.3.18.5. Market Strategy
- 11.3.19. Eurofins DiscoverX.
  - 11.3.19.1. Overview
  - 11.3.19.2. Segments and Product
  - 11.3.19.3. Key Financials
  - 11.3.19.4. Market Developments
  - 11.3.19.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations